These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 19174560)
1. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Pitts TM; Morrow M; Kaufman SA; Tentler JJ; Eckhardt SG Mol Cancer Ther; 2009 Feb; 8(2):342-9. PubMed ID: 19174560 [TBL] [Abstract][Full Text] [Related]
2. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. Sato A; Asano T; Ito K; Asano T J Urol; 2012 Dec; 188(6):2410-8. PubMed ID: 23088964 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956 [TBL] [Abstract][Full Text] [Related]
4. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447 [TBL] [Abstract][Full Text] [Related]
5. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548 [TBL] [Abstract][Full Text] [Related]
6. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977 [TBL] [Abstract][Full Text] [Related]
7. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023 [TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773 [TBL] [Abstract][Full Text] [Related]
10. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. Barbone D; Cheung P; Battula S; Busacca S; Gray SG; Longley DB; Bueno R; Sugarbaker DJ; Fennell DA; Broaddus VC PLoS One; 2012; 7(12):e52753. PubMed ID: 23300762 [TBL] [Abstract][Full Text] [Related]
11. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Zang Y; Kirk CJ; Johnson DE Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039 [TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells. Gatti L; Benedetti V; De Cesare M; Corna E; Cincinelli R; Zaffaroni N; Zunino F; Perego P J Inorg Biochem; 2012 Aug; 113():94-101. PubMed ID: 22717676 [TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. Hong YS; Hong SW; Kim SM; Jin DH; Shin JS; Yoon DH; Kim KP; Lee JL; Heo DS; Lee JS; Kim TW Int J Oncol; 2012 Jul; 41(1):76-82. PubMed ID: 22552540 [TBL] [Abstract][Full Text] [Related]
15. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. Carew JS; Medina EC; Esquivel JA; Mahalingam D; Swords R; Kelly K; Zhang H; Huang P; Mita AC; Mita MM; Giles FJ; Nawrocki ST J Cell Mol Med; 2010 Oct; 14(10):2448-59. PubMed ID: 19583815 [TBL] [Abstract][Full Text] [Related]
16. Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Spratlin JL; Pitts TM; Kulikowski GN; Morelli MP; Tentler JJ; Serkova NJ; Eckhardt SG Anticancer Res; 2011 Apr; 31(4):1093-103. PubMed ID: 21508352 [TBL] [Abstract][Full Text] [Related]
17. [Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism]. Jiang XJ; Meng FY; Zhou HS; Wang Q; Wu FQ; Huang KK; Huang M; Wang ZX; Chen WW Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):537-42. PubMed ID: 22338177 [TBL] [Abstract][Full Text] [Related]
18. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Santo L; Hideshima T; Kung AL; Tseng JC; Tamang D; Yang M; Jarpe M; van Duzer JH; Mazitschek R; Ogier WC; Cirstea D; Rodig S; Eda H; Scullen T; Canavese M; Bradner J; Anderson KC; Jones SS; Raje N Blood; 2012 Mar; 119(11):2579-89. PubMed ID: 22262760 [TBL] [Abstract][Full Text] [Related]
19. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973 [TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]